The Johns Hopkins GLP-1 Paper Becomes the Actuarial Cover for Off-Label Type 1 Prescribing
A Nature Medicine paper from Johns Hopkins of 175,000 type 1 patients found GLP-1 use cut major adverse cardiovascular events 15 percent and end-stage kidney disease 19 percent.